Compare AXT Inc (AXTI) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AXT Inc vs BioNano Genomics Inc — how do they compare? AXT Inc trades at $79.2 (market cap $4.83B), while BioNano Genomics Inc trades at $1.19 (market cap $13.66M). The key difference: AXT Inc is far larger — about 353.6× BioNano Genomics Inc's market cap, and AXT Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| AXTI | BNGO | |
|---|---|---|
Market Cap | $4.83B | $13.66M |
Sector | Technology | Health |
52-Week High | $140.83 | $4.92 |
52-Week Low | $2.05 | $1.06 |
Enterprise Value | $4.50B | $16.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXTI is trading at $76.84, up 4.11% with strong bullish momentum following better-than-expected Q2 2026 earnings. The stock shows bullish technical signals with support at $72 and resistance at $77. Recent financials indicate a turnaround with Q2 EPS of $0.19 beating estimates and revenue growth driven by record indium phosphide demand for AI data centers.
The outlook appears positive with strong AI-driven demand and capacity expansion plans, though valuation metrics remain elevated with P/S of 30.53. Key risks include execution challenges in meeting demand and competitive pressures in the semiconductor substrate market. Analyst consensus is strongly bullish with 73% buy ratings and $72.50 price target.
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AXT Inc
AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.
Read more on AXTI →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
